News & Events
NANETS 2025: Reimagining Treatment for Carcinoid Syndrome
Tom BeveridgeGlobal Product Lead, Paltusotine for Carcinoid Syndrome For individuals living with carcinoid syndrome (CS), a condition caused by neuroendocrine tumors (NETs), severe symptoms such as flushing, diarrhea and abdominal pain can significantly disrupt daily life. Despite the dedication of clinicians, researchers, and advocates, treatment options remain limited – both for controlling the symptoms of CS and addressing the underlying cancer that drives them. At Crinetics, we are focused on bringing forward the next generation of treatments that are purposefully built to treat both NETs and CS.
READ MORECrinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effects SAN DIEGO, October 23, 2025 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced three abstracts from its clinical development programs will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Meeting (NANETS 2025), taking place October 23-25, 2025, in Austin, Texas. “At the 2025 NANETS annual meeting, we are excited to showcase the continued progress of multiple development programs focused on the treatment of neuroendocrine tumors (NETs),” said Dana Pizzuti, M.
READ MORECrinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics grants non-qualified stock option awards to purchase an aggregate of 78,975 shares of its common stock and granted an aggregate of 54,475 restricted stock unit (“RSU”) awards to 20 new non-executive employees
READ MORECrinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
SAN DIEGO – October 6, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host a conference call at 4:30 p.
READ MOREA New Era in Acromegaly Care: Putting Patients at the Center
Isabel KalofonosChief Commercial Officer, Crinetics Pharmaceuticals For years, people living with acromegaly have navigated a care landscape that has remained largely unchanged. Often marked by a large treatment burden, managing treatment for the disease can feel just as demanding as the condition itself. At Crinetics, we believe patients deserve better.
READ MORECrinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Acromegaly in Adults
Crinetics announced that the U. S. Food and Drug Administration (FDA) approved PALSONIFY™ (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
READ MORECrinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics grants non-qualified stock option awards to purchase an aggregate of 62,475 shares of its common stock and granted an aggregate of 43,800 restricted stock unit (“RSU”) awards to 20 new non-executive employees
READ MORECrinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
Crinetics announced that the U. S. FDA granted Orphan Drug Designation for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia.
READ MORECrinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an aggregate of 53,400 restricted stock unit awards to 27 new non-executive employees.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
